Without financial terms or revenue guidance, the materiality of these orders is unclear. Monitor upcoming quarterly filings for revenue recognition from these orders and for potential follow-on orders that could scale the manufacturing relationship. No immediate trade catalyst.
Price Chart
Executive Summary
Cosmos Health's subsidiary Cana Laboratories received new contract manufacturing orders from Nassington and Verisfield for 253,657 units across multiple pharmaceutical products. The orders involve manufacturing of various medicines and oral solutions, deepening existing partnerships but providing no disclosed financial terms or revenue impact.
Key Facts
- Cana Laboratories received orders for 253,657 units from Nassington and Verisfield
- Products include Gritse oral solutions, Fungofort spray, Paco-4 tablets, dexamethasone oral solution, and Fopropt rectal cream
- No financial terms, revenue contribution, or deal value were disclosed
- Orders come from existing partners, suggesting a deepening relationship but not new client wins
- Company's market cap is approximately $13M, making even modest orders potentially notable
Financial Impact
Undisclosed — no dollar value or revenue impact provided in the release
Risk Factors
- No contract value disclosed, making materiality assessment impossible
- Manufacturing orders may be one-time or low-margin
- Forward-looking statements carry typical execution risks for small-cap pharma manufacturers
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3311294 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 8-K | $0.2530 | awaiting T+20 | — | $0.2610 (+3.16%) |
Oct 16, 2026 10d ago | SC 13G/A | $0.3250 | awaiting T+20 | — | $0.2610 (−19.69%) |
Oct 9, 2026 17d ago | 8-K | $0.3496 | awaiting T+20 | — | $0.2610 (−25.34%) |
Sep 3, 2026 7w ago | Press Release | $0.2660 $0.4300 | ▼ −61.65% | ▼ −62.77% | $0.2610 (+1.88%) |
Aug 19, 2026 9w ago | Press Release | $0.1930 | awaiting T+20 | — | $0.2610 (−35.23%) |
Jul 20, 2026 14w ago | Press Release | $0.2303 $0.2050 | ▼ −10.99% | ▼ −15.11% | $0.2610 (+13.33%) |
Jul 17, 2026 14w ago | Press Release | $0.2348 $0.2179 | ▼ −7.20% | ▼ −11.64% | $0.2610 (+11.16%) |
Jul 16, 2026 14w ago | Press Release | $0.2807 $0.2065 | ▼ −26.43% | ▼ −30.05% | $0.2610 (−7.02%) |
Jul 15, 2026 14w ago | Press Release | $0.2785 $0.2071 | ▼ −25.64% | ▼ −27.98% | $0.2610 (−6.28%) |
Jul 14, 2026 14w ago | Press Release | $0.3071 $0.2198 | ▼ −28.43% | ▼ −30.92% | $0.2610 (−15.01%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers